Cologuard® Blitzes the Marketplace at J.P. Morgan

It’s Super Bowl Sunday in Arizona this weekend, but the healthcare industry’s Super Bowl played out earlier this month at the J.P. Morgan Healthcare Conference in San Francisco.

In a field crowded with established players with big news of their own, including Roche's buzz-worthy acquisition of a major stake in Foundation Medicine, Exact’s ability to deliver on our promises during the past year helped us stand out from the pack. 

Read More

Topics: Investor Relations

Exact Sciences Announces Norton Healthcare to Adopt Cologuard

First and only FDA-approved noninvasive stool DNA screening test for colorectal cancer

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) today announced Norton Healthcare is the first healthcare system in Kentucky to offer Cologuard®, the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. Cologuard makes it easy for average risk patients 50 years and older to get screened at their convenience and in the privacy and comfort of their own home without having to worry about taking time off work to prepare for an invasive procedure.

Read More

Topics: Investor Relations